NEW YORK (GenomeWeb News) – BG Medicine this week posted first quarter revenues of $739,000, down 17 percent from $888,000 in the first quarter of 2013.

The drop stemmed from declines in revenues from both the company's BGM Galectin-3 heart failure test and its services business. BG did $739,000 in galectin-3 sales, down 10 percent from $820,000 in Q1 2013. It posted no service revenue in the quarter, compared to $68,000 in service revenues in the year-ago period.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.